Page 99 - Drug Class Review

Drug Effectiveness Review Project

Drugs Authors: Corey-Bloom et al. 55 To evaluate the efficacy and safety of RIV tartrate for patients with AD Setting: Multi-center (22) rivastigmine rivastigmine placebo 6-12 mg/d 1-4 mg/d N/A 26 weeks 26 weeks 26 weeks 231 233 235 Age between 45 and 89 years; non-childbearing potential for females; criteria for AD according to DSM- IV; probable AD according to NINCDS/ADRDA criteria; mild-to-moderate impairment based on MMSE score between 10 and 26; head CT or MRI consistent with AD within 12 months of inclusion; responsible caregiver who provided written consent

Alzheimer Year: 1998 Country: US Novartis Study design: RCT Sample size: 699

Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs